Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.
J Urol. 2012 Apr;187(4):1473-82. doi: 10.1016/j.juro.2011.11.116. Epub 2012 Feb 17.
Chronic pelvic pain syndrome accounts for 90% of all chronic prostatitis but it has an unknown pathogenesis. We sought to understand the role of mast cells and nerve growth factor in chronic pelvic pain.
Expressed prostatic secretions in men with chronic pelvic pain syndrome and controls were tested for mast cell tryptase and nerve growth factor. Mast cell number, activation status and nerve growth factor expression were examined in the NOD/ShiLtJ experimental autoimmune prostatitis model and in mast cell deficient KitW-sh/KitW-sh mice. Tactile allodynia was quantified using von Frey filaments as a measure of pelvic pain behavior. Inhibitors of mast cell degranulation, histamine receptor antagonists and anti-nerve growth factor neutralizing antibodies were tested to decrease pelvic pain behavior.
Men with chronic pelvic pain syndrome showed increased mast cell tryptase and nerve growth factor in expressed prostatic secretions. In the experimental autoimmune prostatitis model increased total and activated mast cells were observed in the prostate. Mast cell deficient KitW-sh/KitW-sh mice showed attenuated pelvic pain behavior but no difference in inflammatory infiltrates in the prostate from controls. Mice with experimental autoimmune prostatitis also demonstrated increased intraprostatic nerve growth factor compared to that of KitW-sh/KitW-sh mice. Treatment of experimental autoimmune prostatitis with a mast cell stabilizer combined with a histamine 1 receptor antagonist resulted in a synergistic decrease in chronic pelvic pain. In contrast, neutralization of nerve growth factor in vivo did not result in pain relief.
Results suggest that mast cells are important mediators of chronic pelvic pain in experimental autoimmune prostatitis cases. They may be potential targets for therapeutic intervention in men with chronic prostatitis/chronic pelvic pain syndrome.
慢性骨盆疼痛综合征占所有慢性前列腺炎的 90%,但其发病机制尚不清楚。我们试图了解肥大细胞和神经生长因子在慢性骨盆疼痛中的作用。
检测慢性骨盆疼痛综合征男性和对照组的前列腺分泌物中的肥大细胞胰蛋白酶和神经生长因子。在 NOD/ShiLtJ 实验性自身免疫性前列腺炎模型和肥大细胞缺陷 KitW-sh/KitW-sh 小鼠中检查肥大细胞数量、激活状态和神经生长因子表达。使用 von Frey 纤维定量触觉过敏,作为评估骨盆疼痛行为的一种手段。测试肥大细胞脱颗粒抑制剂、组胺受体拮抗剂和抗神经生长因子中和抗体,以减少骨盆疼痛行为。
慢性骨盆疼痛综合征男性的前列腺分泌物中肥大细胞胰蛋白酶和神经生长因子增加。在实验性自身免疫性前列腺炎模型中,前列腺中观察到总肥大细胞和激活的肥大细胞增加。肥大细胞缺陷 KitW-sh/KitW-sh 小鼠表现出减轻的骨盆疼痛行为,但前列腺中的炎症浸润与对照组无差异。与 KitW-sh/KitW-sh 小鼠相比,实验性自身免疫性前列腺炎小鼠的前列腺内神经生长因子也增加。用肥大细胞稳定剂联合组胺 1 受体拮抗剂治疗实验性自身免疫性前列腺炎可协同减轻慢性骨盆疼痛。相比之下,体内中和神经生长因子并没有缓解疼痛。
结果表明,肥大细胞是实验性自身免疫性前列腺炎慢性骨盆疼痛的重要介质。它们可能是慢性前列腺炎/慢性骨盆疼痛综合征男性治疗干预的潜在靶点。